PromarkerEndo latest results presented at world congress
Filed with ASX · · 16 pages · English
• The results consolidate earlier prototype models into a universal test with a simple ‘traffic light’ risk score - low, moderate, or high - indicating the likelihood of endometriosis for any patient • PromarkerEndo test now offers a real-world solution for patients with symptoms or considering fertility treatments by diagnosing early-stage endometriosis • Results from a study of 704 participants
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- Chinese patent granted for OxiDx technology
- Share Purchase Plan Offer Booklet
- $4.5m placement to launch Promarker diagnostics
- Trading Halt
- Pause in Trading
Later from Proteomics International Laboratories
- $12 million capital raise completed with oversubscribed SPP
- A landmark in non-invasive Esophageal Cancer diagnosis
- Supplementary Prospectus
- PromarkerD launched into the US at major diabetes conference
- First patent for endometriosis blood test - granted in Japan
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories